Editorial: Targeting α-Synuclein in Parkinson's Disease and Multiple System Atrophy

Front Neurol. 2022 Jun 10:13:942313. doi: 10.3389/fneur.2022.942313. eCollection 2022.

Lisa Fellner¹, Franziska Richter^{2

3}, Patrik Brundin^{4

5}, Johannes Haybaeck^{6

7}

¹ Department of Genomics, Stem Cell Biology and Regenerative Medicine, Institute of Molecular Biology and Center for Molecular Biosciences Innsbruck, Leopold-Franzens-University Innsbruck, Innsbruck, Austria.
² Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Hanover, Germany.
³ Center for Systems Neuroscience, Hanover, Germany.
⁴ Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.
⁵ Pharma Research and Early Development (pRED), F Hoffman-La Roche, Little Falls, NJ, United States.
⁶ Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.
⁷ Diagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, Graz, Austria.

No abstract available

Keywords: Lewy bodies (LBs); Parkinson's disease (PD); glial cytoplasmic inclusions (GCIs); multiple system atrophy (MSA); α-synuclein.

Publication types